NCT05779930View on ClinicalTrials.gov

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2035

Conditions
Acute Lymphoblastic Leukemia, in RelapseNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma RefractoryAcute Lymphoblastic Leukemia With Failed RemissionB-cell Non Hodgkin LymphomaB Cell Leukemia
Interventions
BIOLOGICAL

CD19 specific Chimeric Antigen Receptor T Cell

Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
lead

Nationwide Children's Hospital

OTHER